Search

Adolescence can be challenging for all kids, but especially for those who are Deaf or hard-of-hearing. New resources developed by The Kids Research Institute Australia aim to make life a little easier.

The Kids Research Institute Australia’s Perioperative Medicine team is helping to change global and local practice by finding safer and gentler ways to both undertake surgery, and care for kids and families afterwards.

The Kids Research Institute Australia is helping scientists across the globe inch their way towards clinical trials which could, at last, provide relief for children and families dealing with CDKL5.

COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.

Researchers went into 79 WA primary and secondary schools in 2020 and found increased levels of emotional distress among students and families.

The first ever National Healthy Skin Guideline has become the gold standard for the treatment, prevention and public health control of skin infections in Indigenous populations in Australia and provides a positive framework for healthy skin.

Supporting parents of trans and gender diverse kids.

Research

The Multidimensional Adolescent Functioning Scale (MAFS) is a 23-item, self-report questionnaire assessing psychosocial functioning in adolescents aged 12-17 years. It captures three domains of functioning: 'general functioning', 'family-related functioning', and 'peer-related functioning'. The original English version has good psychometric properties. The aim of the current paper was to translate the MAFS to Dutch and to investigate the psychometric properties of this translation.

Research

We conducted a methylome-wide association study to examine associations between DNA methylation in whole blood and central adiposity and body fat distribution, measured as waist circumference, waist-to-hip ratio and waist-to-height ratio adjusted for body mass index, in 2684 African-American adults in the Atherosclerosis Risk in Communities study.

Research

There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma.